Background: Alzheimer’s disease (AD) is defined in vivo by evidence of amyloid and tau, usually accompanied by neurodegeneration, in accordance with the ATN criteria.Method: Deposition of amyloid is thought to begin early in the disease process and, by the time symptoms become evident, can usually be detected as elevated PET signal in a stereotypical pattern across regions. In contrast tau deposition begins later in disease and the pattern and timing of evolution of tau deposition may vary across individuals. Thus, it is more difficult to assign a classification of tau positive that fits all purposes.Result: Studies in autopsy confirmed patients indicate that tau PET visual interpretation methods may be effective in identifying subjects at the B3 (Braak V/VI) stage of deposition. B3 tau deposition is typically also associated with amyloid positivity, thus predicting a likely pathological diagnosis of high AD neuropathologic change at autopsy. However, a negative visual interpretation cannot rule out the presence of amyloid and tau levels sufficient to support a classification of intermediate AD neuropathological change. Quantitative methods focused on temporal lobe (particularly inferior and mesial temporal lobe) may be more sensitive to earlier stages of AD tau deposition, but confirmation of amyloid status may be required to rule out primary age‐related tauopathy.Conclusion: Together visual and quantitative interpretation methods may identify patterns of tau distribution and density with implications for the expression of symptoms, and future progression of impairment, and may be of value in stratifying/selecting patients most likely to respond in clinical trials of AD therapeutics.